We develop, produce and market active ingredients for pharmaceutical and biotechnological industries to more than 70 countries and 3,000 clients.
STRATEGIC APIS:
- MINOCYCLINE HCl – Antibiotic
- LYMECYCLINE – Antibiotic
- TETRACYCLINE HCl – Antibiotic
- RIVAROXABAN – Anticoagulant
- CLOMIPHENE CITRATE – Fertility
- OXYTETRACYCLINE Ca – Antibiotic
- CLOBUTINOL HCl – Antitussive
- ANASTROZOLE – Oncology
- BISOPROLOL FUMARATE – Antihypertensive
- ENOXAPARINE SODIUM – Anticoagulant
- PIPERACILLIN + TAZOBACTAM – Antibiotic
- TRIMEBUTINE MALEATE – Antiemetic
- VALSARTAN – Antihypertensive
- GABAPENTIN – Antiepileptics
- IMATINIB MESYLATE – Oncology
- COLISTIMETHATE SODIUM – Antibiotic
- QUETIAPINE FUMARATE – Antipsychotic
- MUPIROCIN Ca – Antibiotic
RESEARCH & DEVELOPMENT:
| API | USO | LANZAMIENTO GENÉRICO ESPERADO EN EUROPA |
| APIXABAN | ANTICOAGULANT | 26-May |
| BOSUTINIB | ONCOLOGY | 28-Jan |
| COBICISTAT | ANTIRETROVIRAL | 24-Sep |
| DOLUTEGAVIR SODIUM | ANTIRETROVIRAL | 29-Jan |
| ENZALUTAMIDE | ONCOLOGY | 24-Dec |
| MIRABEGRON | UROLOGY | 28-Jun |
| SELEXIPAG | PULMONAR HYPERTENSION | 29-Apr |
| TICAGRELOR | ANTIPLATELET AGENT | 27-Oct |
| UMECLIDINIUM BROMIDE | COPD | 26-Nov |
| VORTIOXETINE | ANTIDEPRESSANT | ABRIL - 27 |
